We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Medtronic plc (MDT) is a leading medical devices business with stocks listed in the US. It opened the day at US$126 after a previous close of US$124.8. During the day the price has varied from a low of USD125.75 to a high of USD128.29. The latest price was USD127.75 (25 minute delay). Medtronic is listed on the NYSE. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| Open | US$126 |
|---|---|
| High | US$128.29 |
| Low | US$125.75 |
| Close | US$127.75 |
| Previous close | US$124.8 |
| Change | US$2.95 |
| Change % | 2.3638% |
| Volume | 7,172,725 |
| 52-week range | US$96.9878 - US$135.2259 |
|---|---|
| 50-day moving average | US$129.2177 |
| 200-day moving average | US$127.2048 |
| Target price | US$145.56 |
| PE ratio | 44.6835 |
| Dividend yield | US$2.37 (1.9%) |
| Earnings per share (TTM) | US$2.859 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $127.75
| 1 month (2021-09-17) | -1.50% |
|---|---|
| 3 months (2021-07-17) | 1.91% |
| 6 months (2021-04-16) | 1.46% |
| 1 year (2020-10-16) | 16.00% |
|---|---|
| 2 years (2019-10-17) | 17.73% |
| 3 years (2018-10-17) | 31.31% |
| 5 years (2016-10-17) | 54.72% |
Valuing Medtronic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medtronic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Medtronic's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 45x. In other words, Medtronic shares trade at around 45x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Medtronic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.2871. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medtronic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Medtronic's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$9.2 billion (£6.7 billion).
The EBITDA is a measure of a Medtronic's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | US$31.6 billion |
|---|---|
| Operating margin TTM | 20.42% |
| Gross profit TTM | US$19.8 billion |
| Return on assets TTM | 4.34% |
| Return on equity TTM | 7.66% |
| Profit margin | 12.29% |
| Book value | 38.289 |
| Market capitalisation | US$171.9 billion |
TTM: trailing 12 months
There are currently 8.5 million Medtronic shares held short by investors – that's known as Medtronic's "short interest". This figure is 20.2% down from 10.6 million last month.
There are a few different ways that this level of interest in shorting Medtronic shares can be evaluated.
Medtronic's "short interest ratio" (SIR) is the quantity of Medtronic shares currently shorted divided by the average quantity of Medtronic shares traded daily (recently around 3.8 million). Medtronic's SIR currently stands at 2.26. In other words for every 100,000 Medtronic shares traded daily on the market, roughly 2260 shares are currently held short.
However Medtronic's short interest can also be evaluated against the total number of Medtronic shares, or, against the total number of tradable Medtronic shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Medtronic's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Medtronic shares in existence, roughly 10 shares are currently held short) or 0.0063% of the tradable shares (for every 100,000 tradable Medtronic shares, roughly 6 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Medtronic.
Find out more about how you can short Medtronic stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Medtronic.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 26.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Medtronic's overall score of 26.86 (as at 12/31/2018) is nothing to write home about – landing it in it in the 41st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Medtronic is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.07/100
Medtronic's environmental score of 4.07 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 15.28/100
Medtronic's social score of 15.28 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 9/100
Medtronic's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Medtronic is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Medtronic scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Medtronic hasn't always managed to keep its nose clean.
Medtronic plc was last rated for ESG on: 2019-01-01.
| Total ESG score | 26.86 |
|---|---|
| Total ESG percentile | 40.62 |
| Environmental score | 4.07 |
| Environmental score percentile | 5 |
| Social score | 15.28 |
| Social score percentile | 5 |
| Governance score | 9 |
| Governance score percentile | 5 |
| Level of controversy | 3 |
Dividend payout ratio: 46.36% of net profits
Recently Medtronic has paid out, on average, around 46.36% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.97% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Medtronic shareholders could enjoy a 1.97% return on their shares, in the form of dividend payments. In Medtronic's case, that would currently equate to about $2.37 per share.
While Medtronic's payout ratio might seem fairly standard, it's worth remembering that Medtronic may be investing much of the rest of its net profits in future growth.
Medtronic's most recent dividend payout was on 14 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 22 September 2021 (the "ex-dividend date").
Medtronic's shares were split on a 2:1 basis on 26 September 1999. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Medtronic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Medtronic shares which in turn could have impacted Medtronic's share price.
Over the last 12 months, Medtronic's shares have ranged in value from as little as US$96.9878 up to US$135.2259. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Medtronic's is 0.8238. This would suggest that Medtronic's shares are less volatile than average (for this exchange).
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Shares in the trans-Tasman dairy company are down 55% over the last 12 months.
eBay is smashing prices on best-selling tech for Black Friday and Christmas shoppers - save up to 80%.
The 2021 Nissan Navara is widely viewed as the best Navara Nissan has made, outright. It's got excellent specs, an extremely attractive design, fantastic load-lugging and carrying capabilities, and an eager powertrain.
Shares in the Brisbane-based lender have risen nearly 60% in the last 12 months.
The 10 biggest movers on the ASX for Wednesday 13 October 2021.
Everything we know about the Tissue Repair IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Illuvium (ILV) token as well as a list of exchanges you can trade it on.
Westpac shares are up 43% over the past 12 months.
Airports, travel agents and pubs are set to soar post lockdown, but should share investors look beyond immediate short-term wins?
